Latest / Stock Picking with Fexingo: Individual Equities, Research, and Building a Concentrated Portfolio
Why Pfizer Is the Contrarian Dividend Play of 2026
Pfizer just jumped six and a half percent in a week while the rest of the market wobbles. Lucas and Luna dig into the pharma giant's turnaround story: what's driving the rebound, how it fits into a concentrated portfolio, and whether the dividend is finally safe. They weigh the drug pipeline, the patent cliff, and the balance sheet against the market's shifting mood. With interest rate uncertainty still swirling, they ask: is Pfizer a value trap or a genuine contrarian opportunity? Tune in for a grounded look at one stock that's quietly defying the tech rotation.
#Pfizer…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.